ITGB7 (integrin subunit beta 7) is a transmembrane integrin that functions primarily in cell adhesion and leukocyte migration. As a component of the α4β7 integrin complex, ITGB7 mediates heterotypic cell-cell adhesion and cell-matrix interactions through integrin-mediated signaling pathways 1. The protein serves as a homing receptor expressed on thymus-seeding progenitors and is variable among plasma cell populations in myeloma 2. Clinically, ITGB7 has multiple disease relevance pathways. In multiple myeloma, oncogenic ITGB7 overexpression promotes cell-adhesion mediated drug resistance through enhanced plasma cell-stromal cell interactions, with epigenetic regulation via chr12 remodeling at its super-enhancer in high-risk cytogenetic subgroups 3. ITGB7 expression is associated with fulminant type 1 diabetes through a genome-wide significant locus (rs3782151 in CSAD/lnc-ITGB7-1), distinct from classical autoimmune type 1 diabetes 4. In triple-negative breast cancer, ITGB7 participates in immune microenvironment reshaping by targeting glycolysis, correlating with regulatory T cell and macrophage infiltration while predicting poor prognosis 5. Additionally, ITGB7 is implicated in immune checkpoint inhibitor toxicities through integrin-mediated immune cell interactions 6. Importantly, UniProt indicates ITGB7 binds HIV-1 gp120, facilitating viral entry into gut-associated lymphoid tissue, potentially triggering AIDS progression.